Two-stage models for the analysis of cancer screening data

R. Brookmeyer, N. E. Day

Research output: Contribution to journalArticle

Abstract

Methods are proposed for the analysis of the natural history of disease from screening data when it cannot be assumed that untreated preclinical disease always progresses to clinical disease. The methodology is based on a two-stage model for preclinical disease in which stage 1 lesions may or may not progress to stage 2, but all stage 2 lesions progress to clinical disease. The focus is on joint estimation of the total preclinical duration and the sensitivity of the screening test. A partial likelihood is proposed for the analysis of prospectively collected screening data, and an analogous conditional likelihood is proposed for retrospective data. Some special cases for the joint sojourn distribution of the two stages are considered, including the independent model and limiting models where the duration of stage 2 is short relative to stage 1. The methods are applied to a case-control study of cervical cancer screening in Northeast Scotland.

Original languageEnglish (US)
Pages (from-to)657-669
Number of pages13
JournalBiometrics
Volume43
Issue number3
StatePublished - 1987

Fingerprint

Two-stage Model
Early Detection of Cancer
Screening
Cancer
screening
neoplasms
Joints
uterine cervical neoplasms
duration
disease models
Conditional Likelihood
Partial Likelihood
case-control studies
Case-control Study
Scotland
Uterine Cervical Neoplasms
methodology
Case-Control Studies
Limiting
Methodology

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Agricultural and Biological Sciences (miscellaneous)
  • Applied Mathematics
  • Statistics and Probability
  • Public Health, Environmental and Occupational Health

Cite this

Brookmeyer, R., & Day, N. E. (1987). Two-stage models for the analysis of cancer screening data. Biometrics, 43(3), 657-669.

Two-stage models for the analysis of cancer screening data. / Brookmeyer, R.; Day, N. E.

In: Biometrics, Vol. 43, No. 3, 1987, p. 657-669.

Research output: Contribution to journalArticle

Brookmeyer, R & Day, NE 1987, 'Two-stage models for the analysis of cancer screening data', Biometrics, vol. 43, no. 3, pp. 657-669.
Brookmeyer, R. ; Day, N. E. / Two-stage models for the analysis of cancer screening data. In: Biometrics. 1987 ; Vol. 43, No. 3. pp. 657-669.
@article{c24ce554bd014f379e23a8d0a4a05fda,
title = "Two-stage models for the analysis of cancer screening data",
abstract = "Methods are proposed for the analysis of the natural history of disease from screening data when it cannot be assumed that untreated preclinical disease always progresses to clinical disease. The methodology is based on a two-stage model for preclinical disease in which stage 1 lesions may or may not progress to stage 2, but all stage 2 lesions progress to clinical disease. The focus is on joint estimation of the total preclinical duration and the sensitivity of the screening test. A partial likelihood is proposed for the analysis of prospectively collected screening data, and an analogous conditional likelihood is proposed for retrospective data. Some special cases for the joint sojourn distribution of the two stages are considered, including the independent model and limiting models where the duration of stage 2 is short relative to stage 1. The methods are applied to a case-control study of cervical cancer screening in Northeast Scotland.",
author = "R. Brookmeyer and Day, {N. E.}",
year = "1987",
language = "English (US)",
volume = "43",
pages = "657--669",
journal = "Biometrics",
issn = "0006-341X",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Two-stage models for the analysis of cancer screening data

AU - Brookmeyer, R.

AU - Day, N. E.

PY - 1987

Y1 - 1987

N2 - Methods are proposed for the analysis of the natural history of disease from screening data when it cannot be assumed that untreated preclinical disease always progresses to clinical disease. The methodology is based on a two-stage model for preclinical disease in which stage 1 lesions may or may not progress to stage 2, but all stage 2 lesions progress to clinical disease. The focus is on joint estimation of the total preclinical duration and the sensitivity of the screening test. A partial likelihood is proposed for the analysis of prospectively collected screening data, and an analogous conditional likelihood is proposed for retrospective data. Some special cases for the joint sojourn distribution of the two stages are considered, including the independent model and limiting models where the duration of stage 2 is short relative to stage 1. The methods are applied to a case-control study of cervical cancer screening in Northeast Scotland.

AB - Methods are proposed for the analysis of the natural history of disease from screening data when it cannot be assumed that untreated preclinical disease always progresses to clinical disease. The methodology is based on a two-stage model for preclinical disease in which stage 1 lesions may or may not progress to stage 2, but all stage 2 lesions progress to clinical disease. The focus is on joint estimation of the total preclinical duration and the sensitivity of the screening test. A partial likelihood is proposed for the analysis of prospectively collected screening data, and an analogous conditional likelihood is proposed for retrospective data. Some special cases for the joint sojourn distribution of the two stages are considered, including the independent model and limiting models where the duration of stage 2 is short relative to stage 1. The methods are applied to a case-control study of cervical cancer screening in Northeast Scotland.

UR - http://www.scopus.com/inward/record.url?scp=0023597976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023597976&partnerID=8YFLogxK

M3 - Article

C2 - 3663822

AN - SCOPUS:0023597976

VL - 43

SP - 657

EP - 669

JO - Biometrics

JF - Biometrics

SN - 0006-341X

IS - 3

ER -